Biodexa Pharmaceuticals Plc

NasdaqCM:BDRX Stock Report

Market Cap: US$2.5m

Biodexa Pharmaceuticals Management

Management criteria checks 3/4

Biodexa Pharmaceuticals' CEO is Stephen Stamp, appointed in Sep 2019, has a tenure of 5.25 years. total yearly compensation is £252.00K, comprised of 99.2% salary and 0.8% bonuses, including company stock and options. directly owns 0% of the company’s shares, worth $4.24. The average tenure of the management team and the board of directors is 2.5 years and 7.6 years respectively.

Key information

Stephen Stamp

Chief executive officer

UK£252.0k

Total compensation

CEO salary percentage99.2%
CEO tenure5.3yrs
CEO ownership0.0002%
Management average tenure2.5yrs
Board average tenure7.6yrs

Recent management updates

Recent updates

Midatech Pharma regains compliance with Nasdaq's minimum bid price requirement

Oct 18

Midatech Pharma reports 1H results

Sep 14

Midatech surges on the promise of drug delivery system

Jun 17

CEO Compensation Analysis

How has Stephen Stamp's remuneration changed compared to Biodexa Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-UK£7m

Mar 31 2024n/an/a

-UK£7m

Dec 31 2023UK£252kUK£250k

-UK£7m

Sep 30 2023n/an/a

-UK£8m

Jun 30 2023n/an/a

-UK£8m

Mar 31 2023n/an/a

-UK£8m

Dec 31 2022UK£238kUK£236k

-UK£8m

Sep 30 2022n/an/a

-UK£7m

Jun 30 2022n/an/a

-UK£5m

Mar 31 2022n/an/a

-UK£5m

Dec 31 2021UK£329kUK£187k

-UK£5m

Sep 30 2021n/an/a

-UK£7m

Jun 30 2021n/an/a

-UK£8m

Mar 31 2021n/an/a

-UK£15m

Dec 31 2020UK£193kUK£175k

-UK£22m

Jun 30 2020n/an/a

-UK£22m

Mar 31 2020n/an/a

-UK£16m

Dec 31 2019UK£207kUK£50k

-UK£9m

Compensation vs Market: Stephen's total compensation ($USD315.62K) is below average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Stephen's compensation has increased whilst the company is unprofitable.

CEO

Stephen Stamp (62 yo)

5.3yrs

Tenure

UK£252,003

Compensation

Mr. Stephen A. Stamp serves as Chief Financial Officer and Director of Biodexa Pharmaceuticals Plc (formerly known as Midatech Pharma plc) since September 9, 2019. He serves as Chief Executive Officer at B...

Leadership Team

NamePositionTenureCompensationOwnership
Stephen Stamp
CEO, CFO5.3yrsUK£252.00k0.00017%
$ 4.2
Daniel Palmer
Vice President of Technology3.9yrsno datano data
Nicola Tuckwell
VP & Head of Clinical Operations1.1yrsno datano data
Steve Ellul
Chief Business Officerless than a yearno datano data
Fiona Sharp
Group Financial Controllerno datano datano data

2.5yrs

Average Tenure

Experienced Management: BDRX's management team is considered experienced (2.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Stephen Stamp
CEO, CFO5.3yrsUK£252.00k0.00017%
$ 4.2
Simon Turton
Senior Independent Non-Executive Director10yrsUK£31.92k0.00017%
$ 4.2
Stephen Parker
Independent Non-Executive Chairman2.5yrsUK£82.00kno data
Daniel McCurdy
Member of Scientific Advisory Boardno datano datano data
Sijmen de Vries
Independent Non-Executive Director20.2yrsUK£31.92k0.00017%
$ 4.2
Michael Natan
Member of Scientific Advisory Boardno datano datano data
Francesco Stellaci
Chairman of Scientific Advisory Boardno datano datano data
David Male
Member of Scientific Advisory Boardno datano datano data
Lorraine O'Driscoll
Member of Scientific Advisory Boardno datano datano data
Soledad Penades
Member of Scientific Advisory Boardno datano datano data
Jean-Christophe Roux
Member of Scientific Advisory Boardno datano datano data
Silke Krol
Member of Scientific Advisory Boardno datano datano data

7.6yrs

Average Tenure

65yo

Average Age

Experienced Board: BDRX's board of directors are considered experienced (7.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 00:30
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biodexa Pharmaceuticals Plc is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aydin HuseynovLadenburg Thalmann & Company
Savvas NeophitouPanmure Liberum Historic (Panmure Gordon)
Jens LindqvistSinger Capital Markets